Previously submitted to: JMIR Public Health and Surveillance (no longer under consideration since Mar 19, 2020)
Date Submitted: Mar 19, 2020
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Cross-countries comparison of Case Fatality Rates of COVID-19/SARS-COV-2
ABSTRACT
Objective:
Given the importance of case fertility rate (CFR) and recovery rate (RR), we observed different countries during a COVID-19 ongoing epidemic using recent country-level data.
Methods:
data were revived from most accurate databases, including Worldometer, WHO, and Center of Disease Control and Prevention (CDC), and the Morbidity and Mortality Weekly Report (MMWR) series provided from CDC, according to the user’s guide of data sources for patient registries. Then we calculated CFR and RR from various countries.
Results:
The comparison of CFR between different countries with total cases equal or more than 1000 were observed. In addition, all countries with less than 1000 cases were given in details. Current data shows Iraq with only 71 cases has the highest CFR as 9.86%, which strikingly are higher than overall CFR of 3.61%. Overall RR was 55.83%.
Conclusions:
Taking detailed and accurate medical history, and scoring case fatality alongside recovery rate, may show the highest risk areas, to direct the efficient medical care ; thus, this will lead to develop point-of-care tools to help clinicians in stratifying patients based on possible r Clinical Trial: None
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.